229 related articles for article (PubMed ID: 23527138)
1. The nucleocapsid protein of Rift Valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses.
Xu W; Watts DM; Costanzo MC; Tang X; Venegas LA; Jiao F; Sette A; Sidney J; Sewell AK; Wooldridge L; Makino S; Morrill JC; Peters CJ; Kan-Mitchell J
PLoS One; 2013; 8(3):e59210. PubMed ID: 23527138
[TBL] [Abstract][Full Text] [Related]
2. Overlapping CD8+ and CD4+ T-cell epitopes identification for the progression of epitope-based peptide vaccine from nucleocapsid and glycoprotein of emerging Rift Valley fever virus using immunoinformatics approach.
Adhikari UK; Rahman MM
Infect Genet Evol; 2017 Dec; 56():75-91. PubMed ID: 29107145
[TBL] [Abstract][Full Text] [Related]
3. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.
López-Gil E; Lorenzo G; Hevia E; Borrego B; Eiden M; Groschup M; Gilbert SC; Brun A
PLoS Negl Trop Dis; 2013; 7(7):e2309. PubMed ID: 23875044
[TBL] [Abstract][Full Text] [Related]
4. Genetically Modified Rabies Virus Vector-Based Rift Valley Fever Virus Vaccine is Safe and Induces Efficacious Immune Responses in Mice.
Zhang S; Hao M; Feng N; Jin H; Yan F; Chi H; Wang H; Han Q; Wang J; Wong G; Liu B; Wu J; Bi Y; Wang T; Sun W; Gao Y; Yang S; Zhao Y; Xia X
Viruses; 2019 Oct; 11(10):. PubMed ID: 31597372
[TBL] [Abstract][Full Text] [Related]
5. HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgenic mice against ocular herpes.
Srivastava R; Khan AA; Spencer D; Vahed H; Lopes PP; Thai NT; Wang C; Pham TT; Huang J; Scarfone VM; Nesburn AB; Wechsler SL; BenMohamed L
J Immunol; 2015 Mar; 194(5):2232-48. PubMed ID: 25617474
[TBL] [Abstract][Full Text] [Related]
6. Comparison of enzyme-linked immunosorbent assay systems using rift valley fever virus nucleocapsid protein and inactivated virus as antigens.
Yu F; Adungo F; Konongoi SL; Inoue S; Sang R; Ashur S; Kwallah AO; Uchida L; Buerano CC; Mwau M; Zha Y; Nie Y; Morita K
Virol J; 2018 Nov; 15(1):178. PubMed ID: 30466469
[TBL] [Abstract][Full Text] [Related]
7. A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep.
Faburay B; Lebedev M; McVey DS; Wilson W; Morozov I; Young A; Richt JA
Vector Borne Zoonotic Dis; 2014 Oct; 14(10):746-56. PubMed ID: 25325319
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.
Lagerqvist N; Näslund J; Lundkvist A; Bouloy M; Ahlm C; Bucht G
Virol J; 2009 Jan; 6():6. PubMed ID: 19149901
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.
Warimwe GM; Lorenzo G; Lopez-Gil E; Reyes-Sandoval A; Cottingham MG; Spencer AJ; Collins KA; Dicks MD; Milicic A; Lall A; Furze J; Turner AV; Hill AV; Brun A; Gilbert SC
Virol J; 2013 Dec; 10():349. PubMed ID: 24304565
[TBL] [Abstract][Full Text] [Related]
10. Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.
Srivastava R; Khan AA; Garg S; Syed SA; Furness JN; Vahed H; Pham T; Yu HT; Nesburn AB; BenMohamed L
J Virol; 2017 Jan; 91(2):. PubMed ID: 27847359
[TBL] [Abstract][Full Text] [Related]
11. HLA-A*0201 T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus nucleocapsid and spike proteins.
Tsao YP; Lin JY; Jan JT; Leng CH; Chu CC; Yang YC; Chen SL
Biochem Biophys Res Commun; 2006 May; 344(1):63-71. PubMed ID: 16630549
[TBL] [Abstract][Full Text] [Related]
12. Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.
Ikegami T; Hill TE; Smith JK; Zhang L; Juelich TL; Gong B; Slack OA; Ly HJ; Lokugamage N; Freiberg AN
J Virol; 2015 Jul; 89(14):7262-76. PubMed ID: 25948740
[TBL] [Abstract][Full Text] [Related]
13. Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice.
Jansen van Vuren P; Tiemessen CT; Paweska JT
PLoS One; 2011; 6(9):e25027. PubMed ID: 21949840
[TBL] [Abstract][Full Text] [Related]
14. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge.
Boshra H; Lorenzo G; Rodriguez F; Brun A
Vaccine; 2011 Jun; 29(27):4469-75. PubMed ID: 21549790
[TBL] [Abstract][Full Text] [Related]
15. Identification and Characterization of Rift Valley Fever Virus-Specific T Cells Reveals a Dependence on CD40/CD40L Interactions for Prevention of Encephalitis.
Barbeau DJ; Cartwright HN; Harmon JR; Spengler JR; Spiropoulou CF; Sidney J; Sette A; McElroy AK
J Virol; 2021 Nov; 95(23):e0150621. PubMed ID: 34495703
[TBL] [Abstract][Full Text] [Related]
16. High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.
Gómez CE; Perdiguero B; Cepeda MV; Mingorance L; García-Arriaza J; Vandermeeren A; Sorzano CÓ; Esteban M
J Virol; 2013 Jul; 87(13):7282-300. PubMed ID: 23596307
[TBL] [Abstract][Full Text] [Related]
17. Identification of protective Lassa virus epitopes that are restricted by HLA-A2.
Botten J; Alexander J; Pasquetto V; Sidney J; Barrowman P; Ting J; Peters B; Southwood S; Stewart B; Rodriguez-Carreno MP; Mothe B; Whitton JL; Sette A; Buchmeier MJ
J Virol; 2006 Sep; 80(17):8351-61. PubMed ID: 16912286
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus.
Näslund J; Lagerqvist N; Habjan M; Lundkvist A; Evander M; Ahlm C; Weber F; Bucht G
Virology; 2009 Mar; 385(2):409-15. PubMed ID: 19157482
[TBL] [Abstract][Full Text] [Related]
19. Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep.
Lorenzo G; Martín-Folgar R; Rodríguez F; Brun A
Vaccine; 2008 Sep; 26(41):5255-62. PubMed ID: 18682268
[TBL] [Abstract][Full Text] [Related]
20. Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.
Dodd KA; McElroy AK; Jones ME; Nichol ST; Spiropoulou CF
J Virol; 2013 Jun; 87(11):6161-71. PubMed ID: 23536675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
